Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

ConclusionsPembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma.Clinical TrialClinicalTrials.gov NCT02335411

http://link.springer.com/10.1007/s10120-018-00909-5

Source: Gastric Cancer - March 24, 2019 Category: Gastroenterology Source Type: research